NFJ Investment Group LLC Takes $2.46 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

NFJ Investment Group LLC purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 52,790 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,455,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. increased its holdings in Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 660 shares during the last quarter. Torren Management LLC bought a new position in Supernus Pharmaceuticals during the fourth quarter worth about $49,000. Hantz Financial Services Inc. boosted its holdings in Supernus Pharmaceuticals by 73.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 458 shares during the last quarter. Global Retirement Partners LLC acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $64,000. Finally, Vestcor Inc acquired a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth about $67,000.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $45.85 on Friday. The firm has a market cap of $2.67 billion, a price-to-earnings ratio of -23.88, a price-to-earnings-growth ratio of 0.87 and a beta of 0.56. The stock’s 50-day moving average is $46.74 and its 200-day moving average is $48.82. Supernus Pharmaceuticals, Inc. has a one year low of $42.45 and a one year high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The firm had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. During the same period last year, the company earned $0.40 EPS. The company’s revenue was up 32.4% compared to the same quarter last year. On average, equities analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on SUPN. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Supernus Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.